This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Hunter, K. W. Articles by Crawford, N. P. Search for Related Content PubMed PubMed Citation Articles by Hunter, K. W. Articles by Crawford, N. P. Related Collections Cellular Pathobiology: Cancer Genes and Genomics Tumor Biology Tumor Biology: Invasion and Metastasis

Germ Line Polymorphism in Metastatic Progression

Laboratory of Population Genetics, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland

Requests for reprints: Kent Hunter, Laboratory of Population Genetics, Center for Cancer Research/National Cancer Institute/NIH, Building 41 Room D702, 41 Library Drive, Bethesda, MD 20892-5060. Phone: 301-435-8957; Fax: 301-435-8963; E-mail: hunterk{at}mail.nih.gov.

Somatic genetic analysis of tumors and metastases has yielded a plethora of information regarding genes associated with cancer progression. However, somatic alterations in tumor cells are only one source of variability. Genetic polymorphism may also play a significant role in person-to-person variability in metastasis frequency, raising the intriguing possibility that some individuals could be predisposed to secondary tumor development. The identification and characterization of these polymorphisms may have significant implications for the development of tailored treatment or prevention of recurrent disease. (Cancer Res 2006; 66(3): 1251-4)

This article has been cited by other articles:

				T. M. Habermann, S. S. Wang, M. J. Maurer, L. M. Morton, C. F. Lynch, S. M. Ansell, P. Hartge, R. K. Severson, N. Rothman, S. Davis, et al. Host immune gene polymorphisms in combination with clinical and demographic factors predict late survival in diffuse large B-cell lymphoma patients in the pre-rituximab era Blood, October 1, 2008; 112(7): 2694 - 2702. [Abstract] [Full Text] [PDF]

				S. Qu, J. Long, Q. Cai, X.-O. Shu, H. Cai, Y.-T. Gao, and W. Zheng Genetic Polymorphisms of Metastasis Suppressor Gene NME1 and Breast Cancer Survival Clin. Cancer Res., August 1, 2008; 14(15): 4787 - 4793. [Abstract] [Full Text] [PDF]

				A. Forsti, H. Lei, B. Tavelin, K. Enquist, R. Palmqvist, A. Altieri, G. Hallmans, K. Hemminki, and P. Lenner Polymorphisms in the genes of the urokinase plasminogen activation system in relation to colorectal cancer Ann. Onc., December 1, 2007; 18(12): 1990 - 1994. [Abstract] [Full Text] [PDF]

				A. Matakidou, R. el Galta, E. L. Webb, M. F. Rudd, H. Bridle, the GELCAPS Consortium, T. Eisen, and R. S. Houlston Genetic variation in the DNA repair genes is predictive of outcome in lung cancer Hum. Mol. Genet., October 1, 2007; 16(19): 2333 - 2340. [Abstract] [Full Text] [PDF]

				J. R. Cerhan, S. Wang, M. J. Maurer, S. M. Ansell, S. M. Geyer, W. Cozen, L. M. Morton, S. Davis, R. K. Severson, N. Rothman, et al. Prognostic significance of host immune gene polymorphisms in follicular lymphoma survival Blood, June 15, 2007; 109(12): 5439 - 5446. [Abstract] [Full Text] [PDF]

				B. M. Costa, P. Ferreira, S. Costa, P. Canedo, P. Oliveira, A. Silva, F. Pardal, G. Suriano, J. C. Machado, J. M. Lopes, et al. Association between Functional EGF+61 Polymorphism and Glioma Risk Clin. Cancer Res., May 1, 2007; 13(9): 2621 - 2626. [Abstract] [Full Text] [PDF]